Monoclonal antibody for antagonizing and inhibiting binding of vascular endothelial growth factor to its receptor, and coding sequence

US9580498B2 · kind B2 · utility

Assignee

• SUZHOU STAINWEI BIOTECH INC. · CN

Inventors

• Shiping Luo · 安丰镇, CN
• Hongqun Hu · Suzhou, CN
• Zui Chen · Suzhou, CN
• Mingwen Cai · Suzhou, CN
• Yanan Sun · Zhengzhou, CN
• Haiyun Liu · 安丰镇, CN
• Jianying Zhou · Acton, US
• Xiaoqi Song · Suzhou, CN
• Xiaoya Ping · 安丰镇, CN
• Siyu Chen · Beijing, CN
• Donghong Shi · 安丰镇, CN
• Yiqing Xu · 安丰镇, CN
• Qunmin Zhou · Suzhou, CN

Key dates

• Filing date: Nov 5, 2013
• Grant date: Feb 28, 2017
• Expiry date: Nov 5, 2033

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2317/76
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

A mouse monoclonal antibody for antagonizing and inhibiting binding of a vascular endothelial growth factor (VEGF) and its receptor (VEGF-R), and a heavy chain variable region and light chain variable region amino acid sequence thereof. Also disclosed are a humanized preparation process of the antibody and a heavy chain variable region and light chain variable region amino acid sequence of the humanized antibody. The humanized antibody or its derivative can act as an ingredient of a pharmaceutical composition or be prepared into a suitable pharmaceutical preparation, is administered alone or in combination with a chemotherapy drug or other treatment means, and is used in broad-spectrum treatment of various solid tumors such as colon cancer, breast cancer and rhabdomyosarcoma.